Comparison of Heart Failure Cardiogenic Shock patients with Axillary and Femoral Intra-aortic Balloon Pump: A CSWG report.

Objective: To describe the outcomes of patients receiving axillary (Ax) IABP and compare with those receiving Femoral (Fem) IABP for heart failure related cardiogenic shock (HF-CS).

Background: IABPs are traditionally placed via the femoral artery. Single center studies have shown the utility of axillary placement to promote ambulation.

Outcomes with Impella CP in acute myocardial infarction vs heart failure cardiogenic shock: Insights from the Cardiogenic Shock Working Group.

Background: Impella CP (Abiomed, Danvers, MA) microaxial flow pumps are commonly used in acute myocardial infarction (AMI) and heart failure (HF) cardiogenic shock (CS). Contemporary data from large, unselected populations are needed to understand differences between these groups.

Methods: The Cardiogenic Shock Working Group registry enrolls patients with CS at 36 international sites.

Clinical outcomes of cardiogenic shock patients supported with VA-ECMO: Insights from the Cardiogenic Shock Working Group.

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) use for cardiogenic shock (CS) is increasing worldwide despite conflicting results from randomized trials, which focused on myocardial infarction-related CS (MI-CS).

Methods: We performed a retrospective analysis of the Cardiogenic Shock Working Group multicenter registry to assess outcomes in CS in those supported with VA-ECMO. Continuous variables were presented as mean±SD or median+IQR for normal/non-normal distributions.

Benefits of Supplementing a GLP-1 Type Medication With Physical Activity.

In 2023, more than 100 million US adults-approximately 40% of the adult population-were classified as having obesity. Individuals with obesity often encounter complex health challenges because of physiological changes that alter metabolic processes and gene expression, making weight loss increasingly difficult. Many people with obesity now seek glucagon-like peptide-1 receptor agonists (GLP-1 RA) medications to lose weight and improve their health.

Outcomes of patients supported on Impella 5.5 for more than 14 days: A Cardiogenic Shock Working Group registry analysis.

Background: The Impella 5.5 (ABIOMED, Danvers, MA) is a micro-axial pump that is currently approved for up to 14 days of support in the United States. However, in clinical practice it is being used for longer durations of time, especially as a bridge to heart replacement therapies (HRT).

Clinical management of the Impella 5.5 pump.

The Impella 5.5 (Abiomed, USA) is a catheter-based micro-axial flow pump that has emerged as a vital tool in managing patients with cardiogenic shock (CS). Delivering up to 5.

Treatment adherence patterns for patients with atherosclerotic cardiovascular disease: Patient and provider perspectives.

Background: Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality, affecting more than 500 million individuals globally. National guidelines recommend lipid-lowering therapies (LLTs) as first line agents for both primary and secondary prevention of ASCVD. However, under-prescribing of pharmacologic LLTs and sub-optimal medication adherence remain common problems.

Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists.

Background: Off-label prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may exacerbate health disparities.

Methods: We performed a retrospective analysis of data from the Trilliant Health national all-payer claims database, US Census Bureau data (race, ethnicity, median household income), and Centers for Disease Control and Prevention social vulnerability index (SVI). Patients with prescriptions for GLP-1 RAs approved for type 2 diabetes mellitus (T2DM) between January 1, 2022, and December 31, 2022 were included.

Perceptions of high-sensitivity C-reactive protein testing (hsCRP) in atherosclerotic cardiovascular disease: a US survey on cardiologists and nephrologists.

Introduction: High-sensitivity C-reactive protein (hsCRP) is a biomarker of systemic inflammation (SI) and its elevated level is considered a risk-enhancing factor for cardiovascular disease in primary prevention. This study aimed to understand opinions of US clinicians using hsCRP testing in the management of patients with atherosclerotic cardiovascular disease (ASCVD) with or without chronic kidney disease (CKD).

Materials & Methods: Clinicians who ordered hsCRP testing with evaluation of patient-level data were surveyed, between June 2023-August 2023.

Outcomes With Femoral IABP in Heart Failure and Acute Myocardial Infarction-Related Cardiogenic Shock.

Background: Intra-aortic balloon pump (IABP) insertion has not been shown to improve mortality rates in acute myocardial infarction-related cardiogenic shock (AMI-CS) but is increasingly used in heart failure-related cardiogenic shock (HF-CS).

Objective: We sought to compare IABP-related outcomes in patients with HF-CS and AMI-CS.

Methods: The Cardiogenic Shock Working Group registry was queried for patients with CS receiving femoral IABPs as the first temporary mechanical circulatory support (tMCS) device.

Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America.

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have changed the landscape of diabetes management, obesity treatment, and cardiometabolic health. As a result, GLP-1 utilization has increased significantly over the past few years. However, emerging evidence raises questions about the potential of these medications to widen existing health disparities.

Utilization and Outcomes of Temporary Percutaneous Right Ventricular Assist Devices in Cardiogenic Shock.

Acute right ventricular failure (RVF) is a common finding in cardiogenic shock (CS), yet the optimal method of supporting the failing RV remains unclear. This study aimed to describe CS patients receiving percutaneous right ventricular assist devices (pRVADs) using the multicenter Cardiogenic Shock Working Group (CSWG) registry. Among 6,201 patients with CS, 152 (2.

High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?

Inflammation and dyslipidemia are central to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). While lipid-lowering therapies are the cornerstone of ASCVD prevention and treatment, there are other emerging targets, including inflammation (which has been dubbed the 'residual inflammatory risk'), that can be addressed after LDL cholesterol thresholds have been reached. Research over the past 20 years has identified C-reactive protein (CRP) as a key marker of inflammation with atherosclerosis.

Outcomes of Surgically Implanted Impella Microaxial Flow Pumps in Heart Failure-Related Cardiogenic Shock.

Background: Patients with cardiogenic shock (CS) are increasingly treated with high-profile microaxial flow pumps (Impella 5.5), but little is known about the indications and outcomes of this support strategy in patients with CS due to heart failure (HF-CS).

Objectives: We sought to describe the clinical features and outcomes of patients with HF-CS treated with Impella 5.

International cooperation in cardiogenic shock is key to improving outcomes: Cardiogenic Shock Working Group impacts a single center in a developing country.

The Cardiogenic Shock Working Group (CSWG) is an international research consortium formed in 2016. The National Institute of Cardiology Ignacio Chavez joined in 2021 and launched a cardiogenic shock (CS) program in 2022. This study evaluates the impact of CSWG core standards on outcomes in a middle-income country reference center of 9,430 patients with CS (Society for Cardiovascular Angiography and Interventions [SCAI] stages B→E) from a registry of 28,054 admissions (2005-2023).

Hospital Transfers for Hip Fracture Patients Are Associated With Higher Cost and Mortality.

Background: Transferring hip fracture patients may increase morbidity and cost. The purpose of this study was to examine time to surgery, outcomes, and cost in patients undergoing operative management of displaced femoral neck fractures (DFNFs), comparing those admitted through the emergency department (ED) and those transferred from outside hospitals.

Methods: A retrospective review of surgically managed DFNF patients (age ≥ 65 years) at a single institution between May 29, 2020, and December 29, 2022, was performed.

Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS).

Background: Systemic inflammation (SI) is a risk factor for atherosclerotic cardiovascular disease (ASCVD) and is most commonly assessed by measuring levels of high-sensitivity C-reactive protein (hsCRP).

Objective: This study aimed to determine hsCRP testing rates and SI prevalence in patients with ASCVD and in a subset of patients with chronic kidney disease (CKD).

Methods: This was a retrospective, cross-sectional analysis using US-based data from the Optum® de-identified Electronic Health Record data set (Optum® EHR; 1/1/2017-12/31/2021).

Identification and management of cardiopulmonary risk in patients with COPD: a multidisciplinary consensus and modified Delphi study.

Background: Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary disease (COPD). Yet cardiovascular disease and risk is under diagnosed in COPD and is often undertreated, increasing the risk of cardiopulmonary events.

Methods: We formed a Global Working Group of experts in COPD and cardiovascular disease to produce a consensus statement detailing the identification and management of cardiopulmonary risk in patients with COPD.

Patterns of Prophylactic Anticoagulation Among Patients Hospitalized for COVID-19: An Analysis of the American Heart Association COVID-19 Cardiovascular Disease Registry.

Background: Limited knowledge exists about prophylactic anticoagulation patterns in patients hospitalized for COVID-19.

Methods And Results: We conducted a retrospective cohort study using American Heart Association COVID-19 Cardiovascular Disease Registry data from May 2020 to March 2022. We included patients without preexisting indications for or contraindications to anticoagulation, excluding those with missing anticoagulation data.

Single-Center Experience of Omitting Preprocedure Transesophageal Echo for MitraClip Patients.

•Mitral transcatheter edge-to-edge repair requires preprocedure echocardiography.•In certain circumstances, timeliness of transesophageal echos can be a limitation.•Using transthoracic echo results, heart teams may decide to proceed with repair.

Building a culture of healthy living in the workplace.

Workplace settings, including hybrid, remote, and home-based environments, are key places to support employees and their families to live healthfully since so many adults spend significant amounts of time at work. Employers can create a culture of healthy living at their workplaces and do so intentionally through process and practice. They can establish organizational policies, systems, work processes, architectural design practices, and employment benefits designs to support healthy behaviors for their employees and their families.